



OPEN ACCESS

ORIGINAL ARTICLE

CM-Score: a validated scoring system to predict *CDKN2A* germline mutations in melanoma families from Northern Europe

Thomas P Potjer,¹ Hildur Helgadóttir,² Mirjam Leenheer,¹ Nienke van der Stoep,¹ Nelleke A Gruis,³ Veronica Höiom,² Håkan Olsson,⁴ Remco van Doorn,³ Hans F A Vasen,⁵ Christi J van Asperen,¹ Olaf M Dekkers,⁶ Frederik J Hes,¹ on behalf of the Dutch Working Group for Clinical Oncogenetics

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2017-105205>).

¹Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands

²Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

³Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands

⁴Department of Oncology, Lund University and Skåne University Hospital, Lund, Sweden

⁵Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands

⁶Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands

Correspondence to

Dr Frederik J Hes, Department of Clinical Genetics, Leiden University Medical Centre, Leiden 2333 ZA, the Netherlands; F.J.Hes@lumc.nl

Received 12 December 2017

Revised 9 March 2018

Accepted 22 March 2018



© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Potjer TP, Helgadóttir H, Leenheer M, et al. *J Med Genet* 2018;**55**:661–668.

ABSTRACT

Background Several factors have been reported that influence the probability of a germline *CDKN2A* mutation in a melanoma family. Our goal was to create a scoring system to estimate this probability, based on a set of clinical features present in the patient and his or her family.

Methods Five clinical features and their association with *CDKN2A* mutations were investigated in a training cohort of 1227 Dutch melanoma families (13.7% with *CDKN2A* mutation) using multivariate logistic regression. Predefined features included number of family members with melanoma and with multiple primary melanomas, median age at diagnosis and presence of pancreatic cancer or upper airway cancer in a family member. Based on these five features, a scoring system (*CDKN2A Mutation (CM)-Score*) was developed and subsequently validated in a combined Swedish and Dutch familial melanoma cohort (n=421 families; 9.0% with *CDKN2A* mutation).

Results All five features were significantly associated ($p < 0.05$) with a *CDKN2A* mutation. At a CM-Score of 16 out of 49 possible points, the threshold of 10% mutation probability is approximated (9.9%; 95% CI 9.8 to 10.1). This probability further increased to >90% for families with ≥ 36 points. A CM-Score under 16 points was associated with a low mutation probability ($\leq 4\%$). CM-Score performed well in both the training cohort (area under the curve (AUC) 0.89; 95% CI 0.86 to 0.92) and the external validation cohort (AUC 0.94; 95% CI 0.90 to 0.98).

Conclusion We developed a practical scoring system to predict *CDKN2A* mutation status among melanoma-prone families. We suggest that *CDKN2A* analysis should be recommended to families with a CM-Score of ≥ 16 points.

INTRODUCTION

Since its identification in 1994,¹ the *CDKN2A* gene (MIM 600160) has remained the major high-risk susceptibility gene for cutaneous melanoma. Germline mutations are present in approximately 10%–40% of familial cases.² Carriers of a germline mutation in the *CDKN2A* gene have an increased risk for developing melanoma, with a penetrance of up to 70% at 80 years of age, and 40% of carriers

develop multiple primary cutaneous melanomas.³ Furthermore, mutation carriers have an increased risk for other types of malignancies, the most important of which is pancreatic cancer (PC).⁴ Due to the high risk of melanomas and other types of cancer and the advantages of regular surveillance in improving prognosis and survival,^{5,6} it is important to identify families that carry a *CDKN2A* germline mutation. However, the probability of a *CDKN2A* mutation strongly depends both on the clinical characteristics of a family and personal (dermatological) and environmental factors such as skin type and the amount of sun exposure. Thus, *CDKN2A* mutation analysis might not be indicated in some lower-risk melanoma families.

The Netherlands and Sweden both have a high incidence of melanoma (age-standardised rate 19.4 and 18.0 per 100 000, respectively)⁷ and specific founder mutations in the *CDKN2A* gene are the predominant cause of *familial* melanoma in these countries. In the Netherlands, the 19-base pair deletion termed p16-Leiden (c.225_243del, p.Ala76Cysfs*64; RefSeq NM_000077.4) confers an increased risk for melanoma and for tumours of the pancreas and upper airway tract (larynx, pharynx, oral cavity) and to a lesser extent tumours of the lungs and digestive tract.^{8–10} Carriers of the Swedish founder mutation (c.335_337dup, p.Arg112dup; RefSeq NM_000077.4) also show an increased risk for these tumours.^{11,12} Although it is recognised that the risk-spectrum for non-melanoma cancers differs among carriers of different mutations in the *CDKN2A* gene, pancreatic and upper airway tract cancers have repeatedly been reported in a variety of carrier populations.^{4,13–17}

Over the past decade, research groups from Europe, USA and Australia have attempted to identify clinical features that are associated with germline *CDKN2A* mutations in melanoma families.^{18–24} Studied features included (1) number of patients with melanoma in a family, (2) number of patients with multiple primary melanomas (MPMs) in a family, (3) median age at diagnosis of melanoma and (4) presence of PC in a family. The most significant associations reported in these studies were the presence of more than two melanoma cases in a family, an early age of onset and having at least

one family member with MPMs and/or PC. Based on a literature review from 2009, it was suggested that patients with melanoma from areas with a moderate to high incidence of melanoma are candidates for genetic testing of *CDKN2A* if they have at least three primary melanomas or when there are at least two additional diagnoses of melanoma and/or PC among close (first-degree or second-degree) family members ('rule of threes').²⁵ The authors argued that these families have an estimated 10% or greater probability of carrying a germline *CDKN2A* mutation, which is a commonly used threshold in clinical practice for gene sequencing in hereditary cancer.^{26–28}

The goal of this study was to create a scoring system for clinicians to estimate the probability of a germline *CDKN2A* mutation based on a set of clinical features present in the patient and his or her family. Using a training cohort of Dutch melanoma families, we therefore analysed the association of four previously reported clinical features that are associated with a *CDKN2A* mutation and investigated the association with upper airway cancer (UAC) as an additional feature. A combined cohort of Swedish and Dutch melanoma families was used for external validation of the scoring system.

PATIENTS AND METHODS

Training cohort

The training cohort included all index patients with cutaneous melanoma and their families in the Netherlands referred for *CDKN2A* mutation analysis between 1998 and 2015. According to current Dutch referral guidelines, *CDKN2A* mutation analysis is indicated if one of the following criteria is met: a family with (1) two first-degree relatives with melanoma, (2) two first-degree or second-degree relatives with melanoma and one first-degree or second-degree relative with PC, (3) three or more primary melanomas in one individual, (4) an individual with juvenile melanoma (<18 years) or (5) an individual with a history of both melanoma and PC. At the Department of Clinical Genetics at Leiden University Medical Centre, the Laboratory for Diagnostic Genome Analysis (LDGA) has been the primary sequencing facility for *CDKN2A* in the Netherlands since 1998 and receives diagnostic requests from across the Netherlands. Essential pedigree information was gathered for the families and added to the Leiden Familial Melanoma Database. These data included the number of first-degree and second-degree family members (of each other) with cutaneous melanoma (invasive or in situ), whether these patients had a single melanoma or MPMs, the age of each patient with melanoma at first diagnosis and the number of family members with PC and UAC, that is, cancer of larynx, pharynx or oral cavity. We restricted our analysis of these latter tumours to the first-degree and second-degree relatives of the index patient and the first-degree relatives of patients with melanoma. We relied on the referring clinical geneticists for complete pedigree information and, if necessary, histological confirmation of cancer diagnoses (melanoma and others). We included all information on cancer diagnoses and also those unconfirmed by the clinical geneticist, since index patient reports of melanomas in family members have a high known level of accuracy (true positive predictive value 77%–87%).²⁹ We imputed the age of melanoma diagnosis for family members where the age at diagnosis was not reported in the pedigree (n=320 individuals from 212 families (61 with *CDKN2A* mutation)). Imputation was based on median age at diagnosis in *CDKN2A* mutation families (40 years) and in sporadic (non-*CDKN2A*) patients (55 years), as reported by van der Rhee *et al.*³⁰ When the patient was younger than this age or was deceased prior to this age at time of *CDKN2A*

analysis in the family, that specific age was used for imputation. Families without a *CDKN2A* mutation were excluded from the study if *CDKN2A* analysis was only performed in a non-affected family member (n=84). Families in which *CDKN2A* sequencing was unsuccessful were also excluded (n=4). The Leiden University Medical Centre Ethics Committee issued a declaration of no objection (#C14.064) regarding the creation of the Leiden Familial Melanoma Database.

Validation cohort

The greater portion of the validation cohort in this study consisted of members of melanoma-prone families from Sweden.³¹ Families were identified by questioning patients with newly diagnosed melanoma about their familial melanoma history. Melanoma families were defined as kindreds with at least two relatives (first-degree, second-degree or third-degree) with histologically or clinically verified melanoma. Since 1995, germline *CDKN2A* mutation analysis is offered to members of these families after informed consent is obtained. The study was approved by Research Ethical Review Boards at Lund University and Karolinska Institute in Stockholm, the sites where the genetic tests were performed. In Stockholm, patients with MPMs (regardless of family history) are also invited to undergo germline *CDKN2A* mutation analysis. In 2012, a study was performed to broaden understanding of the identified familial melanoma kindreds and of patients with MPMs through linkage to Swedish national registries.^{11 12 32 33} Further linkage to the Swedish Cancer Registry (established in 1958 with register completeness estimated to be 96%³⁴) provided data on all registered cancers in the *CDKN2A* genotyped individuals and their first-degree and second-degree relatives.

Additional Dutch melanoma families were recruited at the Department of Dermatology, Leiden University Medical Centre, according to the inclusion criteria of the GenoMEL study (<http://www.genomel.org/>). After providing written informed consent, patients with melanoma were asked about their familial melanoma history. A melanoma family was defined by the presence of three or more cases with histologically confirmed melanoma or two cases with histologically confirmed melanoma in first-degree relatives.

DNA analysis

In the Dutch cohorts (both training and validation), DNA was extracted from whole blood samples of index patients and was used for sequencing of all coding exons of *CDKN2A* (1α, 1β, 2 and 3), including exon/intron boundaries. To detect larger deletions or duplications, multiplex ligation-dependent probe amplification was performed. In the early years of *CDKN2A* diagnostics, analysis was limited to a mutation-specific PCR for the detection of the p16-Leiden mutation. However, only a very small subset of *CDKN2A* wild type families in the training cohort was analysed in this manner (n=32). In an additional 89 families from the training cohort, exon 1β was not sequenced. For the Swedish cohort, procedures used for PCR of all *CDKN2A* exons and direct sequencing of PCR products have been described previously.¹¹ Presence of a *CDKN2A* mutation was defined as having either a pathogenic or likely pathogenic variant in the *CDKN2A* gene (class 4 or 5 variant)³⁵ or an unclassified variant (class 3) shown to be located on a pathogenic *CDKN2A* haplotype. Classification of these variants was based on (previously reported) cosegregation with disease, strong evidence of impaired protein function and, in some families, shared pathogenic haplotypes.

Table 1 Univariate analysis showing the independent association between each clinical feature and a germline *CDKN2A* mutation

Features	Total (n=1227)	<i>CDKN2A</i> wild type (n=1059)	<i>CDKN2A</i> mutation (n=168)	OR*	95% CI	P values
No of family members with melanoma†						
1	374	346	28 (7.5%)	1.0	–	–
2	503	461	42 (8.3%)	1.1	0.7 to 1.9	0.641
3	233	194	39 (16.7%)	2.5	1.5 to 4.2	<0.001
≥4	117	58	59 (50.4%)	12.6	7.4 to 21.3	<0.001
No of family members with MPMs‡						
0	749	697	52 (6.9%)	1.0	–	–
1	406	329	77 (19.0%)	3.1	2.2 to 4.6	<0.001
≥2	72	33	39 (54.2%)	15.8	9.2 to 27.3	<0.001
Median age at primary diagnosis						
≥50 years	437	422	15 (3.4%)	1.0	–	–
30–50 years	666	532	134 (20.1%)	7.1	4.1 to 12.3	<0.001
<30 years	124	105	19 (15.3%)	5.1	2.5 to 10.4	<0.001
Presence of pancreatic cancer‡						
No	956	877	79 (8.3%)	1.0	–	–
Yes	271	182	89 (32.8%)	5.4	3.9 to 7.6	<0.001
Presence of upper airway cancer‡						
No	1117	999	118 (10.6%)	1.0	–	–
Yes	110	60	50 (45.5%)	7.1	4.6 to 10.7	<0.001

*The variable with the smallest risk was defined as baseline with an OR of 1.0, and ORs for the other variables were calculated against this baseline value.

†First-degree and second-degree relatives of each other, including the index patient.

‡First-degree and second-degree relatives of the index patient and first-degree relatives of patients with melanoma.

MPMs, multiple primary melanomas.

Statistical analysis

Five clinical features were predefined and used for analysis: (1) the total number of first-degree and second-degree family members (including the index patient) with a diagnosis of melanoma, (2) the number of these family members with MPMs, (3) the median age at diagnosis of (first) melanoma in the family and the presence of (4) PC and (5) UAC in a family. Median age at diagnosis was divided into three age groups (<30 years, 30–50 years and ≥50 years). A univariate analysis was performed to independently evaluate these features and a multivariate logistic regression model was used to assess the association between all five features and the presence of a germline *CDKN2A* mutation. The formula of the logistic regression model is $P(\text{probability}) = e^L / (1 + e^L)$ where $L = \text{constant} + \beta_1 * C_1$ (number of family members with melanoma [1=0, 2=1, 3=2, ≥4=3]) + $\beta_2 * C_2$ (number of family members with MPMs [0=0, 1=1, ≥2=2]) + $\beta_3 * C_3$ (median age at primary diagnosis [≥50=0, <50=1]) + $\beta_4 * C_4$ (presence of PC [No=0, Yes=1]) + $\beta_5 * C_5$ (presence of UAC [No=0, Yes=1]) and where β is the feature-specific β -coefficient. All statistical analyses were carried out in SPSS V.23.0.

Development of a scoring system: CM-Score

The β -coefficients derived from the multivariate analysis were converted to points for each feature using the formula $\text{Points} = (C_x * \beta_c) / B$ (as described by Sullivan *et al.*³⁶ where C_x is the feature-specific numeral from the logistic regression formula, β_c is the β -coefficient and B is the fixed multiplier or constant (defined 0.22). The total number of points was calculated for each family in the training cohort. Since there were often considerable differences in the number of families with successive point totals (for instance, there were 6 families with 21 points (33% mutation) and 37 families with 22 points (16% mutation)), the cohort was subsequently split into eight point-groups. This grouping would ensure a more accurate calculation of the observed mutation frequencies per group with narrower CIs.

For each of these groups, the observed mutation frequencies, the mean of the predicted probabilities and their 95% CIs were calculated. The scoring system, CM-(*CDKN2A* Mutation) Score, was subsequently applied to the validation cohort, with the families split into the same point-groups as in the training cohort. The observed mutation frequencies and their 95% CIs were again calculated for each group. The performance of the scoring system was assessed for both the training cohort and the validation cohort with the Hosmer-Lemeshow goodness of fit test (calibration) and receiver operator characteristic (ROC) curve analysis with calculation of the area under the curve (AUC) (discrimination). The slope of the calibration line was estimated with linear regression. The proposed cut-off value in CM-Score for performing *CDKN2A* analysis was determined as the score that corresponds to a predicted mutation probability of ~10%.^{26–28}

RESULTS

Training cohort

A total of 1227 families were included in the study, 168 of which had a (likely) pathogenic variant in the *CDKN2A* gene (13.7%). The p16-*Leiden* founder mutation was present in 77% of these families (n=130) (online supplementary table S1). Most of the families had two or more members with melanoma (853 families; 70%) and included 503 two-case families, 233 three-case families and 117 families with four or more melanoma cases. In 654 (77%) of these multiple-case families, at least one additional clinical feature was present (ie, median age <50 years or presence of MPMs, PC or UAC in the family, see online supplementary table S2). In the 374 single-case families, 207 families (55%) had at least two other clinical features and 150 families (40%) had one other clinical feature. The majority of melanomas in the training cohort were confirmed by histology reports (76%). PC and UAC diagnoses were less frequently confirmed by the referring clinical geneticist (both 43%).

Table 2 Multivariate logistic regression model showing the association between all five clinical features combined and a germline *CDKN2A* mutation

Clinical feature	β -coefficient	OR	95% CI	P values
No of family members with melanoma (1, 2, 3, ≥ 4)	0.871	2.4	1.9 to 3.0	<0.001
No of family members with MPMS (0, 1, ≥ 2)	1.096	3.0	2.2 to 4.1	<0.001
Median age at primary diagnosis (≥ 50 , <50)	2.142	8.5	4.5 to 16.0	<0.001
Presence of pancreatic cancer (No, Yes)	2.013	7.5	4.8 to 11.7	<0.001
Presence of upper airway cancer (No, Yes)	1.790	6.0	3.4 to 10.5	<0.001

The formula of the logistic regression model:

$P = e^L / (1 + e^L)$ where $L = -6.220 + 0.871 \times C_1$ (no. of family members with melanoma [$1=0, 2=1, 3=2, \geq 4=3$]) + $1.096 \times C_2$ (no. of family members with MPMS [$0=0, 1=1, \geq 2=2$]) + $2.142 \times C_3$ (median age at primary diagnosis [$\geq 50=0, <50=1$]) + $2.013 \times C_4$ (presence of pancreatic cancer [$No=0, Yes=1$]) + $1.790 \times C_5$ (presence of upper airway cancer [$No=0, Yes=1$]). MPMS, multiple primary melanomas.

Univariate and multivariate analysis

Having at least three family members with melanoma was significantly associated with the presence of a *CDKN2A* mutation in the univariate analysis (table 1). A median age of under 50 years and one or more cases with MPMS in a family were also significantly associated with a *CDKN2A* mutation. Age under 30 years at time of diagnosis did not result in a higher OR than age 30–50 years (OR 5.1 (95% CI 2.5 to 10.4) versus OR 7.1 (95% CI 4.1 to 12.3), respectively). A significantly increased risk for a *CDKN2A* mutation was seen in families in which PC and UAC co-occurred with melanoma; a mutation was present in 33% of the families with one or more patients with PC and 46% of the families with one or more patients with UAC.

In a multivariate logistic regression model, the five features investigated in the univariate model remained significantly associated with a mutation (table 2). Since in the univariate analysis, age under 30 years was not a stronger predictor than age 30–50 years, these age groups were combined into one group (<50 years) for the multivariate analysis. The highest ORs were found for median age under 50 years (OR 8.5 (95% CI 4.5 to 16.0)) and for presence of PC or UAC in a family (OR 7.5 (95% CI 4.8 to 11.7) and OR 6.0 (95% CI 3.4 to 10.5), respectively), but these features had only two possible outcomes (<50 or ≥ 50 years, Yes or No), whereas the other melanoma-specific features had three or four possible outcomes and increasing ORs for each step.

CM-Score

The points assigned to each clinical feature are shown in table 3. The predicted mutation probabilities and observed mutation frequencies per point-group are shown in table 4. Below a total of 16 of 49 possible points, the predicted mutation probability is low ($\leq 4.0\%$). Between 16 and 19 points, the predicted mutation probability is 9.9% and substantially increases in subsequent point-groups (20–23 points: 20.9%, 24–27 points: 34.7%, 28–31 points: 52.1%, 32–35 points: 71.4%, ≥ 36 points: 90.7%).

The concordance between observed and predicted mutation probabilities (calibration) is graphically displayed in figure 1A. The slope of the calibration line (1.03) indicates a good calibration, and the Hosmer-Lemeshow test ($p=0.925$) provided no

Table 3 Scoring system (CM-Score) based on the multivariate logistic regression model

Features	Points
No of family members with melanoma*	
1	0
2	4
3	8
≥ 4	12
No of family members with MPMS*	
0	0
1	5
≥ 2	10
Median age at primary diagnosis	
≥ 50 years	0
<50 years	10
Presence of pancreatic cancer	
No	0
Yes	9
Presence of upper airway cancer	
No	0
Yes	8

*First-degree and second-degree relatives of each other, including the index patient.

†First-degree and second-degree relatives of the index patient and first-degree relatives of patients with melanoma.

MPMS, multiple primary melanomas.

evidence of a poor fit. Figure 2A shows the ROC curve analysis. The AUC is 0.89 (95% CI 0.86 to 0.92, $p<0.001$), which indicates that the model has a good ability to discriminate between families with and without a *CDKN2A* mutation. The threshold of 10% predicted probability is approximated at the cut-off value of 16 points in CM-Score, with a sensitivity of 90.5% (95% CI 84.7 to 94.2) and a specificity of 68.0% (95% CI 65.1 to 70.8). The majority of families ($n=736$; 60%) had a CM-Score of less than 16 points.

External validation of the scoring system

The validation cohort consisted of a total of 421 families (403 from Sweden; 18 from the Netherlands), of which 38 had a (likely) pathogenic variant in the *CDKN2A* gene (9.0%). Most of these families ($n=30$; 79%) carried the Swedish founder mutation p.Arg112dup and two Dutch families carried the p16-Leiden founder mutation (online supplementary table S3). The majority were multiple-case families (294 families; 70%) and included 232 two-case families, 37 three-case families and 25 families with four or more melanoma cases. All melanomas in the validation cohort were histologically confirmed. PC was present in 29 families (28 histologically confirmed; 72% *CDKN2A* mutation) and UAC in 24 families (23 histologically confirmed; 63% *CDKN2A* mutation).

The observed mutation frequencies per point-group in the validation cohort are shown in table 4. The performance of CM-Score in the validation cohort is displayed in figures 1B and 2B. The slope of the calibration line is 1.14 with a non-significant Hosmer-Lemeshow test ($p=0.615$). The AUC is 0.94 (95% CI 0.90 to 0.98, $p<0.001$), indicating good performance of CM-Score in the validation cohort. The sensitivity and specificity at the cut-off value of 16 points is 89.5% (95% CI 74.3 to 96.6) and 83.8% (95% CI 79.6 to 87.3), respectively. Similar to the training cohort, the majority of families in the validation cohort ($n=325$; 77%) had a CM-Score of less than 16 points.

Table 4 Point totals from CM-Score with the corresponding mean predicted mutation probabilities and the observed mutation frequencies in the training and validation cohorts

CM-Score	Predicted mutation probability		Observed mutation frequency					
			Training cohort (n=1227)			Validation cohort (n=421)		
Points	Prob. (%)	95% CI	Freq.	%	95% CI	Freq.	%	95% CI
≤11	1.0	0.9 to 1.0	4/383	1.0	0.4 to 2.7	0/159	0	0.0 to 2.4
12–15	4.0	3.9 to 4.1	12/353	3.4	2.0 to 5.9	4/166	2.4	0.9 to 6.0
16–19	9.9	9.8 to 10.1	26/203	12.8	8.9 to 18.1	4/38	10.5	4.2 to 24.1
20–23	20.9	20.4 to 21.4	18/99	18.2	11.8 to 26.9	1/17	5.9	1.1 to 27.0
24–27	34.7	33.1 to 36.3	23/75	30.7	21.4 to 41.8	4/12	33.3	13.8 to 60.9
28–31	52.1	49.4 to 54.7	16/32	50.0	33.6 to 66.4	4/6	66.7	30.0 to 90.3
32–35	71.4	69.6 to 73.1	30/40	75.0	59.8 to 85.8	5/7	71.4	35.9 to 91.8
≥36	90.7	89.0 to 92.4	39/42	92.9	81.0 to 97.5	16/16	100	80.6 to 100.0

The predicted mutation probability for each point-group is the mean of the predicted probabilities of the point totals in that group in the training cohort. The corresponding 95% CI is estimated using the SE of the mean.
Freq, frequency; Prob, probability.

DISCUSSION

This study in a large Dutch training cohort of 1227 melanoma families confirmed the importance of four previously established clinical features that are associated with the presence of a germline *CDKN2A* mutation in a patient with melanoma. Furthermore, a fifth feature, the presence of UAC in the family, could be validated. Based on these clinical features and their ORs in our multivariate logistic regression model, we developed the CM-Score system to predict *CDKN2A* mutation probability, which performed very well in a combined Swedish and Dutch external validation cohort (AUC 0.94). At a cut-off value of 16 out of 49 points, the predicted probability approximates the commonly used 10% predicted probability threshold for germline gene sequencing in hereditary cancer, with a sensitivity of 89% and a specificity of 84% in the validation cohort. This cut-off value is also clinically relevant, since the majority of families in the training and validation cohorts scored less than 16

points (60% and 77%, respectively), a threshold below which the probability of a mutation decreases substantially ($\leq 4\%$). Use of CM-Score could potentially spare many families (extensive) genetic testing, which may be particularly relevant in countries where resources for genetic testing are limited. Conversely, in families with a high CM-Score and therefore high mutation probability, genetic testing is even more urgent. A scoring system should, however, always only complement the clinical judgement of the clinical geneticist requesting DNA diagnostics (for instance, taking into account family size, age of family members, whether a patient has a certain combination of different malignancies and the availability of reliable medical information).

Risk models involving melanoma³⁷ and *CDKN2A* mutation probability^{23 24} have been described previously. Niendorf *et al* incorporated the features (1) number of primary proband melanomas, (2) number of primary melanomas in the family and (3) age in a logistic regression model they named MELPREDICT.²³




Figure 1 Calibration of CM-Score. (A) Training cohort. (B) Validation cohort. The calibration line (red) is a linear regression line that shows the relation between observed mutation frequency and predicted mutation probability in the training cohort (A) and the validation cohort (B). The dashed line is the reference line of perfect calibration. The 95% CIs of the observed mutation frequencies per point-group are displayed by the vertical lines. HL-test, Hosmer-Lemeshow test.




Figure 2 Discriminative ability of CM-Score. (A) Training cohort. (B) Validation cohort. ROC curve analysis of the training cohort (A) and the validation cohort (B). Point total was used as the test variable and mutation status was used as the state variable. Comparable results were obtained when the calculated predicted probability was used as test variable. AUC, area under the curve; ROC, receiver operator characteristic.

The AUC was 0.881 in the training set ($n=116$ families) and 0.803 in the external validation set ($n=143$ families). A computerised optimisation of this model, renamed MelaPRO, was published in 2010 and outperformed the former model with an AUC of 0.86 in a validation set of 167 families.²⁴ MelaPRO includes the same clinical (familial) features as MELPREDICT, but also takes into account regional melanoma incidence rates and the geographical penetrance of *CDKN2A*. In contrast, while our CM-Score was trained and validated using families of Northern European descent, its strength lies in its simple, non-computerised scoring system that incorporates five features (including the presence of PC and UAC in a family) and despite this simplicity shows a superior performance in very large sets of melanoma-prone families.

The guidelines for *CDKN2A* mutation testing proposed by Leachman *et al* in 2009²⁵ were recently updated.³⁸ In view of the recent reports of non-*CDKN2A* melanoma syndromes, such as those related to germline mutations in *BAP1*³⁹ (MIM 603089), *POT1*⁴⁰ (MIM 606478) and *MITF*⁴¹ (MIM 156845), the authors propose tailored multigene panel testing in melanoma families instead of *CDKN2A* mutation testing alone. The 2009 criteria for genetic testing were converted into a points system, with points awarded for cancers that occur in so-called melanoma-dominant syndromes and melanoma-subordinate syndromes (where melanoma is not the predominant cancer type, such as in hereditary breast and ovarian cancer). Based on these points, the clinical geneticist can subsequently select the appropriate gene panel(s) to be tested in a family. In the selection and genetic assessment of melanoma families, this is a rather different approach to the one we propose in the current study. First, CM-Score is designed for families where melanoma is the predominant cancer type. Second, since *CDKN2A* is still by far the major susceptibility gene in familial melanoma, we based the selection of families for genetic assessment on the probability of specifically detecting a *CDKN2A* mutation in these families. Because other melanoma-dominant syndromes (such as those related to *BAP1*, *POT1*,

CDK4 and *MITF*) are very rare compared to *CDKN2A*-related familial melanoma (each gene contributing <1%),⁴² we hypothesise that the calculated mutation probability from CM-Score largely reflects the joint probability of detecting a germline *CDKN2A* mutation or any other melanoma-dominant mutation. However, it should be noted that some tumours that are not part of CM-Score are highly specific to non-*CDKN2A* melanoma syndromes, especially *BAP1*-related tumours such as uveal melanoma and mesothelioma.^{43–44} *BAP1* germline analysis should therefore be specifically offered when these tumours co-occur with cutaneous melanoma in a family, either together with *CDKN2A* or as part of a multigene panel test. It is not within the scope of this study to elaborate on the choice between multigene panel testing and *CDKN2A* mutation testing alone in melanoma-prone families. Although multigene panel testing increases the detection rate of cancer-predisposing germline mutations, there is also an elevated risk of identifying a variant of unknown significance in one of the genes and therefore increasing the uncertainty for a family regarding their genetic risk. The chance of this happening increases as more genes are included in a panel or when multiple panels are considered. Pros and cons of multigene panel testing should therefore always be carefully discussed with the patient.

Strengths of our study include relatively large and homogeneous cohorts and the broad analysis of five clinical features, including one more recently described feature (ie, UAC). However, because the scoring system is based on populations with a high melanoma incidence, it is possible that it will underestimate the probability of finding a *CDKN2A* mutation in lower melanoma incidence areas such as Southern (Mediterranean) Europe or overestimate the probability in extreme incidence areas such as Australia. Additional validation in other geographical areas would therefore be valuable. Another limitation of our study is information bias. In the training cohort, we had to rely on information supplied by the referring clinical geneticists and not all melanoma diagnoses were therefore histologically

confirmed (76%). However, since the reporting of additional melanomas in family members by the index patient is known to be highly accurate, this factor is unlikely to have influenced the results.²⁹ Unfortunately, only 43% of all pancreatic tumours and 43% of all upper airway tumours were confirmed. Nevertheless, all melanomas and other cancers in the validation cohort were verified since the majority of diagnoses were derived from the Swedish Cancer Registry.

In conclusion, we have developed and validated a non-computerised and clinically easy-to-use scoring system that shows high utility in predicting the probability of a germline *CDKN2A* mutation in melanoma-prone families from Northern Europe. The scoring system is based on clinical information on melanoma diagnoses in the patient's family and additionally includes diagnoses of PC and UAC. As CM-Score was trained and validated in large sets of Northern European families, we suggest that the system should be further validated in other regions as well. In view of the 10% mutation probability threshold, we suggest that *CDKN2A* analysis should be recommended to families with a CM-Score of ≥ 16 points.

Acknowledgements We are indebted to the participating families, whose generosity and cooperation have made this study possible. We acknowledge the contributions to this work made by Diana Lindén, Lena Westerberg, Anita Schmidt-Zander, Rainer Tuominen and Johan Hansson. We thank Medactie.com for help with editing of this paper.

Collaborators Dutch Working Group for Clinical Oncogenetics (participating members): A Wagner, L van der Kolk, M Ausems, Th Van Os, E M Leter, L Spruijt, K van Engelen, L Berger.

Contributors Design and conception of study: TPP, HFAV, OMD, FJH. Data collection and assembly: TPP, HH, ML, NvdS, NAG, VH, HO. Data analysis and interpretation: TPP, HH, ML, Rvd, HFAV, CJvA, OMD, FJH. Writing of manuscript: TPP, HH, ML, FJH. Critical review and revision of manuscript: all authors. Submission of manuscript: TPP.

Funding This work was supported by the Dutch Cancer Society (UL 2015-7511 and UL 2012-5489); The Swedish Cancer Society (CAN 2013/637, CAN 2014/851 and CAN 2015/283); Genomel (LSHC-CT-2006-018702); ERC advanced grant 2011 (291576); The Radiumhemmet Research Funds (144073) and Regional Funds and Hospital Funds in Lund and Stockholm.

Competing interests None declared.

Patient consent Not required.

Ethics approval Leiden University Medical Centre Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Hussussian CJ, Struwing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. *Nat Genet* 1994;8:15–21.
- Read J, Wadt KA, Hayward NK. Melanoma genetics. *J Med Genet* 2016;53:1–14.
- Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA. Melanoma Genetics Consortium. Geographical variation in the penetrance of *CDKN2A* mutations for melanoma. *J Natl Cancer Inst* 2002;94:894–903.
- Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Res* 2006;66:9818–28.
- van der Rhee JJ, de Snoo FA, Vasen HF, Mooi WJ, Putter H, Gruis NA, Kukutsch NA, Bergman W. Effectiveness and causes for failure of surveillance of *CDKN2A*-mutated melanoma families. *J Am Acad Dermatol* 2011;65:289–96.
- Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. *J Clin Oncol* 2016;34:2010–9.
- Ferlay JS, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray FG. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013. 2013 <http://globocan.iarc.fr> (accessed on Jul 2017).
- Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). *Int J Cancer* 2000;87:809–11.
- de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, Willemze R, Breuning MH, Gruis NA. Increased risk of cancer other than melanoma in *CDKN2A* founder mutation (p16-Leiden)-positive melanoma families. *Clin Cancer Res* 2008;14:7151–7.
- Potjer TP, Kranenburg HE, Bergman W, de Vos tot Nederveen Cappel WH, van Monsjou HS, Barge-Schaapveld DQ, Vasen HF. Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant. *Eur J Hum Genet* 2015;23:711–4.
- Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg A, Olsson H, Hansson J. High risk of tobacco-related cancers in *CDKN2A* mutation-positive melanoma families. *J Med Genet* 2014;51:545–52.
- Helgadottir H, Höiom V, Tuominen R, Jönsson G, Månsson-Brahme E, Olsson H, Hansson J. *CDKN2A* mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. *Int J Cancer* 2015;137:2220–6.
- Goldstein AM. Familial melanoma, pancreatic cancer and germline *CDKN2A* mutations. *Hum Mutat* 2004;23:630.
- Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlov I, Berwick M, Armstrong BK, Krickler A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB. GEM Study Investigators. Risk of non-melanoma cancers in first-degree relatives of *CDKN2A* mutation carriers. *J Natl Cancer Inst* 2012;104:953–6.
- Goldstein AM, Stacey SN, Olafsson JH, Jonsson GF, Helgason A, Sulem P, Sigurgeirsson B, Benediktsson KR, Thorisdottir K, Ragnarsson R, Kjartansson J, Kostic J, Masson G, Kristjansson K, Gulcher JR, Kong A, Thorsteinsdottir U, Rafnar T, Tucker MA, Stefansson K. *CDKN2A* mutations and melanoma risk in the Icelandic population. *J Med Genet* 2008;45:284–9.
- Vinarsky V, Fine RL, Assaad A, Qian Y, Chabot JA, Su GH, Frucht H. Head and neck squamous cell carcinoma in FAMMM syndrome. *Head Neck* 2009;31:1524–7.
- Cabanillas R, Astudillo A, Valle M, de la Rosa J, Álvarez R, Durán NS, Cadiñanos J. Novel germline *CDKN2A* mutation associated with head and neck squamous cell carcinomas and melanomas. *Head Neck* 2013;35:E80–E84.
- Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. Lund Melanoma Study Group/Melanoma Genetics Consortium (GenoMEL). Features associated with germline *CDKN2A* mutations: a GenoMEL study of melanoma-prone families from three continents. *J Med Genet* 2007;44:99–106.
- Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, De Bernardo C, Buccini P, Moscarella E, Panetta C, Ferrari A, Grammatico P, Catricalà C. Clinical features predicting identification of *CDKN2A* mutations in Italian patients with familial cutaneous melanoma. *Cancer Epidemiol* 2011;35:e116–e120.
- Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L, Bressac-de Paillerets B, Avril MF, Demenais F. French Familial Melanoma Study Group. Familial melanoma: clinical factors associated with germline *CDKN2A* mutations according to the number of patients affected by melanoma in a family. *J Am Acad Dermatol* 2012;67:1257–64.
- Harland M, Cust AE, Badenas C, Chang YM, Holland EA, Aguilera P, Aitken JF, Armstrong BK, Barrett JH, Carrera C, Chan M, Gascoyne J, Giles GK, Agha-Hamilton K, Hopper JL, Jenkins MA, Kanetsky PA, Kefford RF, Kolm I, Lowery J, Malvey J, Ogbah Z, Puig-Butille JA, Orihuela-Segalés J, Randerson-Moor JA, Schmid H, Taylor CF, Whitaker L, Bishop DT, Mann GJ, Newton-Bishop JA, Puig S. Prevalence and predictors of germline *CDKN2A* mutations for melanoma cases from Australia, Spain and the United Kingdom. *Heredit Cancer Clin Pract* 2014;12:20.
- Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Atrua

- C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. *J Am Acad Dermatol* 2016;74:325–32.
23. Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. *J Med Genet* 2006;43:501–6.
 24. Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. *Cancer Res* 2010;70:552–9.
 25. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debnjak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. Selection criteria for genetic assessment of patients with familial melanoma. *J Am Acad Dermatol* 2009;61:677.e1–677.e14.
 26. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. *J Clin Oncol* 1996;14:1730–6.
 27. National Institute for Health and Clinical Excellence. *Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer: NICE guidelines: National Collaborating Centre for Cancer (UK)*, 2013.
 28. Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, Howell TA, Tischkowitz M, Laloo F. Pathology update to the Manchester Scoring System based on testing in over 4000 families. *J Med Genet* 2017;54:674–81.
 29. Wadt KA, Drzewiecki KT, Gerdes AM. High accuracy of family history of melanoma in Danish melanoma cases. *Fam Cancer* 2015;14:609–13.
 30. van der Rhee JI, Krijnen P, Gruis NA, de Snoo FA, Vasen HF, Putter H, Kukutsch NA, Bergman W. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. *J Am Acad Dermatol* 2011;65:281–8.
 31. Hansson J, Bergenmar M, Hofer PA, Lundell G, Månsson-Brahme E, Ringborg U, Synnerstad I, Bratell AT, Wennberg AM, Rosdahl I. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. *J Clin Oncol* 2007;25:2819–24.
 32. Helgadottir H, Tuominen R, Olsson H, Hansson J, Höiom V. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. *J Am Acad Dermatol* 2017;77:893–901.
 33. Department of Population and Welfare Statistics. *Multigeneration register 2011. A description of contents and quality*. Örebro, Sweden: Statistics Sweden, 2012:2. http://www.scb.se/statistik/_publikationer/BE9999_2011A01_BR_BE96BR1202.pdf
 34. Socialstyrelsen (The National Board of Health and Welfare). The Swedish Cancer Registry. 2015 <http://www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish>
 35. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat* 2008;29:1282–91.
 36. Sullivan LM, Massaro JM, D'Agostino RB, Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. *Stat Med* 2004;23:1631–60.
 37. Davies JR, Chang YM, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green A, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Lee TK, Le Marchand L, Mackie RM, Olsson H, Østerlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus L, Zens MS, Ziegler A, Gallagher RP, Barrett JH, Newton-Bishop J. Development and validation of a melanoma risk score based on pooled data from 16 case-control studies. *Cancer Epidemiol Biomarkers Prev* 2015;24:817–24.
 38. Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, Ghiorzo P. Identification, genetic testing, and management of hereditary melanoma. *Cancer Metastasis Rev* 2017;36:77–90.
 39. Wiesner T, Obenaus AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rütten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors. *Nat Genet* 2011;43:1018–21.
 40. Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Makowski M, Brown KM, Dunning AM, Keane TM, López-Otin C, Gruis NA, Hayward NK, Bishop DT, Newton-Bishop JA, Adams DJ. POT1 loss-of-function variants predispose to familial melanoma. *Nat Genet* 2014;46:478–81.
 41. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Couplier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fétita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Matéus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demeais F, Ballotti R, Bressac-de Paillerets B. French Familial Melanoma Study Group. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* 2011;480:94–8.
 42. Aoude LG, Wadt KA, Pritchard AL, Hayward NK. Genetics of familial melanoma: 20 years after CDKN2A. *Pigment Cell Melanoma Res* 2015;28:148–60.
 43. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. *J Med Genet* 2011;48:856–9.
 44. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. *Nat Genet* 2011;43:1022–5.